The short version of Synthetic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentadecapeptide | Composed of fifteen amino acid residues |
| Amino acid sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val | Single-letter form GEPPPGKPADDAGLV |
| Original source | Fragment of a protein in human gastric juice | First characterized in the 1990s |
| Number in name | 157 | Refers to the fragment's position in the source protein |
| Human trial evidence | Limited | Preclinical rodent data predominate |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Early work on this family of molecules examined fractions of human gastric juice, where a larger protein was reported to protect gastrointestinal tissue in animal models. BPC 157 was designed as a shorter, more stable fragment of that protein and then studied on its own. The peptide itself is not a normal dietary component and is not present in the human body in meaningful quantities. Descriptions of its origin therefore refer to the research lineage of a laboratory molecule rather than to an endogenous or nutritional substance.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
== Sources == MCD peptide is a component of bumblebee (Megabombus pennsylvanicus) venom. In addition to MCD peptide, melittin and apamin have also been identified in this venom and are also described as voltage-dependent channel blockers. MCD peptide is also present in the venom of the honey bee Apis mellifera.
Abietic acid dermatitis Acid-induced Acrylic monomer dermatitis Adhesive dermatitis African blackwood dermatitis Airbag dermatitis (airbag burn) Alkali-induced Allergic Antifungal agent-induced Antimicrobial agent-induced Arsenic dermatitis Artificial nail-induced Axillary antiperspirant-induced Axillary deodorant-induced Baboon syndrome Black dermatographism Bleaching cream-induced Capsaisin-induced Chemical burn Chloracne Chrome dermatitis Clothing-induced Cobalt dermatitis Contact stomatitis (contact lichenoid reaction, lichenoid amalgam reaction, oral mucosal cinnamon reaction) Contact urticaria Corticosteroid-induced Cosmetic dermatitis Cosmetic intolerance syndrome Dentifrice-induced Dermatitis from metals and metal salts Dust-induced Epoxy resin dermatitis Ethylenediamine-induced Eye makeup-induced Fiberglass dermatitis Flower-induced Formaldehyde-induced Formaldehyde-releasing agent-induced Fragrance-induced Gold dermatitis Hair bleach-induced Hair dye-induced Hair lotion-induced Hair spray-induced Hair straightener-induced Hair tonic-induced Houseplant-induced Hydrocarbon-induced Irritant folliculitis Lacquer dermatitis (lacquer sensitivity) Lanolin-induced Lipstick-induced Local anesthetic-induced Makassar ebony dermatitis Marine plant-induced Mechanical irritant dermatitis Mercury dermatitis Mouthwash-induced Nail lacquer-induced Nail polish remover-induced Nickel dermatitis Occupation-induced p-Chloro-meta-xylenol-induced Paraben-induced Paraphenylenediamine dermatitis Permanent wave preparation-induced Phenothiazine drug-induced Photoallergic Photoirritant Plant derivative-induced Pollen-induced Polyester resin dermatitis Propylene glycol-induced Protein contact dermatitis Quaternium-15 hypersensitivity Reed dermatitis Rosewood dermatitis Rosin dermatitis Rubber dermatitis Seed-induced Shoe dermatitis Solvent-induced Sorbic acid-induced Subjective irritant contact dermatitis (sensory irritant contact dermatitis) Sunscreen-induced Systemic contact dermatitis Tear gas dermatitis Textile dermatitis Traumatic irritant contact dermatitis Tree-associated plant-induced Tree-induced Tulip fingers Urushiol-induced Vegetable-induced
Less frequently employed treatments encompass prostaglandin pellets inserted into the urethra, the injection of smooth-muscle relaxants and vasodilators directly into the penis, penile implants, the use of penis pumps, and vascular surgery.
Sources: en.wikipedia.org
When in point detonate mode the projectile's high explosive detonates when it hits a target. In point detonate delay mode the high explosive detonates a brief instant after it hits a target. The delay is intended to let the projectile first penetrate a wall, and explode when it emerges on the other side. In air burst mode the cannon's aiming system programs the munition to explode in the air above the target. When the gunner aims their sight on the desired target, and presses their trigger halfway, the aiming system calculates the range to the target. They can then raise their sight slightly above the target, and when they pull the trigger all the way the aiming system will instruct the round to explode in the air above the target. Enemies hiding behind an obstacle can then be killed or wounded without blowing a hole through the obstacle. The XM1203 Armor Piercing Fin Stabilized Discarding Sabot with Tracer. The projectile itself is 50 mm in diameter, encasing a long thin dart, designed to pierce armored vehicles. A light "sabot" grips the barrel's rifling, in order for the shell to get the full power of the expanding gas. Tracer rounds have a button of pyrotechnic chemical that leaves a trail to help a gunner observe the trajectory/path of the shot. The XM1202 Target Practice-Tracer round is a full-bore training round 50 mm in diameter. With the intended purpose of drill firing and gun ballistic tests, the XM1202 round likely shares similar ballistic performance to the XM1204 HEAB-T round.
In the United States Code, the IEEPA is Title 50, §§1701–1707. The IEEPA authorizes the president to declare the existence of an "unusual and extraordinary threat ... to the national security, foreign policy, or economy of the United States" that originates "in whole or substantial part outside the United States." It further authorizes the president, after such a declaration, to block transactions and freeze assets to deal with the threat and requires the president to report to Congress every 6 months on the circumstances, threats and actions taken. In the event of an actual attack on the United States, the president can also confiscate property connected with a country, group, or person that aided in the attack. IEEPA falls under the provisions of the National Emergencies Act (NEA), which means that an emergency declared under the act must be renewed annually to remain in effect. The authority given to the president under the IEEPA does not grant him the ability to regulate or prohibit communication that "does not involve a transfer of anything of value", imports or exports of information or any informational materials, or transactions incidental to travel. Donations intended to relieve human suffering, such as food, clothing or medicine are also excluded unless the president specifically finds their inclusion necessary.
=== Immediate-spin cross-matching === Immediate-spin cross-matching (ISCM) is an abbreviated form of cross-matching that is faster, but less sensitive; its primary use is to detect a mismatch between ABO blood types. It is an immediate test that involves combining the patient's serum and donor's red blood cells at room temperature, then centrifuging the sample and observing for agglutination or hemolysis. A lack of agglutination or hemolysis indicates a negative test reaction, or compatible match. ISCM is not appropriate in all circumstances; if the recipient's antibody screen is positive, or if they have had a positive antibody screen in the past, a full crossmatch is performed instead.
=== Bulk measurement === Generally speaking bulk measurement instruments thermally vaporize the particles prior to ionization, and there are several different ways that the vaporization and ionization is performed. The main instrument that is used for bulk measurements is Aerodyne aerosol mass spectrometer (AMS).
Sources: en.wikipedia.org
=== Aglepristone === In cases resulting from progestogen administration aglepristone should be administered subcutaneously twice at a 24-hour interval at a rate of 10 mg/kg for all dogs with severe acromegaly or are diabetic.
=== IATSE strike === Problems kept coming on July 16, when thirty to thirty-five crew members went on strike to demand better wages and benefits, under encouragement from the IATSE union, whose local representative warned that the dispute would cost The Stone Group an additional $40,000 per day. The production was sanctioned by the Directors Guild of America and Screen Actors Guild, but did not recognize other labor groups. As such, the film's technicians were signed to a flat fee. Filming was again suspended but, since Mississippi was a right-to-work state, the concerned workers were summarily fired and fifty new ones were brought in. This included cinematographer Leonetti, who was replaced by Alexander Gruszynski and complained that he stood to lose $50,000 in wages. Meanwhile, on July 17, Bosworth was officially released from his NFL contract by the Seattle Seahawks, although this was expected due to his persistent shoulder issues, and he already considered himself an actor first.
=== Stille–carbonylative cross-coupling === A common alteration to the Stille coupling is the incorporation of a carbonyl group between R1 and R2, serving as an efficient method to form ketones. This process is extremely similar to the initial exploration by Migita and Stille (see History) of coupling organostannane to acyl chlorides. However, these moieties are not always readily available and can be difficult to form, especially in the presence of sensitive functional groups. Furthermore, controlling their high reactivity can be challenging. The Stille-carbonylative cross-coupling employs the same conditions as the Stille coupling, except with an atmosphere of carbon monoxide (CO) being used. The CO can coordinate to the palladium catalyst (9) after initial oxidative addition, followed by CO insertion into the Pd-R1 bond (10), resulting in subsequent reductive elimination to the ketone (12). The transmetalation step is normally the rate-determining step.
Sources: en.wikipedia.org
It is a chain of fifteen amino acids, referred to as a pentadecapeptide. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It corresponds to a fragment of a protein found in human gastric juice.
It is neither a naturally circulating hormone nor an approved medicine in most countries. It is a synthetic peptide fragment used chiefly as a laboratory research material. Its regulatory status varies by jurisdiction, and it is not authorized as a therapeutic product in the United States or the European Union.
Published human evidence is very limited. Most findings come from rodent studies conducted by a small number of groups. As a result, statements about its effects in humans are generally described as uncertain rather than established.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.